vs

Side-by-side financial comparison of INVO Fertility, Inc. (IVF) and Origin Materials, Inc. (ORGN). Click either name above to swap in a different company.

Origin Materials, Inc. is the larger business by last-quarter revenue ($3.0M vs $1.8M, roughly 1.7× INVO Fertility, Inc.). INVO Fertility, Inc. runs the higher net margin — -150.5% vs -6423.8%, a 6273.3% gap on every dollar of revenue. On growth, INVO Fertility, Inc. posted the faster year-over-year revenue change (22.6% vs -67.2%). INVO Fertility, Inc. produced more free cash flow last quarter ($-1.8M vs $-18.0M). Over the past eight quarters, INVO Fertility, Inc.'s revenue compounded faster (12.8% CAGR vs -33.5%).

INVO Fertility, Inc. is a specialized healthcare company focused on delivering accessible assisted reproductive technology solutions. It develops, manufactures and markets the patented INVOcell intravaginal culture system for in vitro fertilization procedures, serving fertility clinics and patients across North America, Europe and other global regions, with a mission to reduce barriers to high-quality fertility care.

Origin Systems, Inc. was an American video game developer based in Austin, Texas. It was founded on March 3, 1983, by Richard Garriott and his brother Robert. Origin is best known for their groundbreaking work in multiple genres of video games, such as the Ultima and Wing Commander series. The company was purchased by Electronic Arts in 1992.

IVF vs ORGN — Head-to-Head

Bigger by revenue
ORGN
ORGN
1.7× larger
ORGN
$3.0M
$1.8M
IVF
Growing faster (revenue YoY)
IVF
IVF
+89.8% gap
IVF
22.6%
-67.2%
ORGN
Higher net margin
IVF
IVF
6273.3% more per $
IVF
-150.5%
-6423.8%
ORGN
More free cash flow
IVF
IVF
$16.2M more FCF
IVF
$-1.8M
$-18.0M
ORGN
Faster 2-yr revenue CAGR
IVF
IVF
Annualised
IVF
12.8%
-33.5%
ORGN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
IVF
IVF
ORGN
ORGN
Revenue
$1.8M
$3.0M
Net Profit
$-2.6M
$-194.1M
Gross Margin
Operating Margin
-93.1%
-6438.5%
Net Margin
-150.5%
-6423.8%
Revenue YoY
22.6%
-67.2%
Net Profit YoY
-62.2%
-1335.6%
EPS (diluted)
$-0.77
$-50.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVF
IVF
ORGN
ORGN
Q4 25
$3.0M
Q3 25
$1.8M
$4.7M
Q2 25
$1.9M
$5.8M
Q1 25
$1.6M
$5.4M
Q4 24
$1.7M
$9.2M
Q3 24
$1.4M
$8.2M
Q2 24
$1.8M
$7.0M
Q1 24
$1.6M
$6.8M
Net Profit
IVF
IVF
ORGN
ORGN
Q4 25
$-194.1M
Q3 25
$-2.6M
$-16.4M
Q2 25
$-5.3M
$-12.7M
Q1 25
$-17.4M
$-26.4M
Q4 24
$-3.6M
$-13.5M
Q3 24
$-1.6M
$-36.8M
Q2 24
$-2.2M
$-19.5M
Q1 24
$-1.6M
$-13.9M
Gross Margin
IVF
IVF
ORGN
ORGN
Q4 25
Q3 25
Q2 25
Q1 25
35.2%
Q4 24
41.4%
Q3 24
31.0%
Q2 24
53.1%
Q1 24
45.3%
Operating Margin
IVF
IVF
ORGN
ORGN
Q4 25
-6438.5%
Q3 25
-93.1%
-363.6%
Q2 25
-160.4%
-257.5%
Q1 25
-1042.1%
-600.8%
Q4 24
-202.0%
-175.7%
Q3 24
-90.7%
-395.1%
Q2 24
-100.9%
-259.6%
Q1 24
-95.7%
-263.7%
Net Margin
IVF
IVF
ORGN
ORGN
Q4 25
-6423.8%
Q3 25
-150.5%
-351.8%
Q2 25
-283.6%
-219.3%
Q1 25
-1060.1%
-486.9%
Q4 24
-211.3%
-146.6%
Q3 24
-113.8%
-448.2%
Q2 24
-122.2%
-277.3%
Q1 24
-101.3%
-203.9%
EPS (diluted)
IVF
IVF
ORGN
ORGN
Q4 25
$-50.17
Q3 25
$-0.77
$-0.11
Q2 25
$-13.30
$-0.09
Q1 25
$-12.53
$-0.18
Q4 24
$14.86
$-17.04
Q3 24
$-15.11
$-0.26
Q2 24
$-22.39
$-0.14
Q1 24
$-7.55
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVF
IVF
ORGN
ORGN
Cash + ST InvestmentsLiquidity on hand
$32.9M
Total DebtLower is stronger
$2.0M
Stockholders' EquityBook value
$5.8M
$104.2M
Total Assets
$18.8M
$157.7M
Debt / EquityLower = less leverage
0.34×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVF
IVF
ORGN
ORGN
Q4 25
$32.9M
Q3 25
$34.1M
Q2 25
$35.3M
Q1 25
$43.8M
Q4 24
$56.3M
Q3 24
$56.4M
Q2 24
$55.7M
Q1 24
$75.8M
Total Debt
IVF
IVF
ORGN
ORGN
Q4 25
Q3 25
$2.0M
Q2 25
$4.8M
Q1 25
Q4 24
$7.5M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IVF
IVF
ORGN
ORGN
Q4 25
$104.2M
Q3 25
$5.8M
$295.0M
Q2 25
$2.6M
$311.1M
Q1 25
$3.3M
$314.6M
Q4 24
$12.7M
$338.4M
Q3 24
$-23.3K
$358.9M
Q2 24
$1.4M
$390.6M
Q1 24
$10.2K
$408.2M
Total Assets
IVF
IVF
ORGN
ORGN
Q4 25
$157.7M
Q3 25
$18.8M
$327.3M
Q2 25
$19.3M
$348.4M
Q1 25
$31.7M
$349.0M
Q4 24
$46.4M
$378.0M
Q3 24
$17.0M
$399.6M
Q2 24
$17.8M
$431.0M
Q1 24
$17.3M
$448.6M
Debt / Equity
IVF
IVF
ORGN
ORGN
Q4 25
Q3 25
0.34×
Q2 25
1.83×
Q1 25
Q4 24
0.59×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVF
IVF
ORGN
ORGN
Operating Cash FlowLast quarter
$-1.8M
$-8.9M
Free Cash FlowOCF − Capex
$-1.8M
$-18.0M
FCF MarginFCF / Revenue
-101.6%
-596.6%
Capex IntensityCapex / Revenue
0.5%
301.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-7.8M
$-63.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVF
IVF
ORGN
ORGN
Q4 25
$-8.9M
Q3 25
$-1.8M
$-8.1M
Q2 25
$-1.7M
$-7.3M
Q1 25
$-3.5M
$-8.4M
Q4 24
$-617.4K
$-5.7M
Q3 24
$-640.8K
$-13.4M
Q2 24
$-1.5M
$-15.0M
Q1 24
$-260.6K
$-16.7M
Free Cash Flow
IVF
IVF
ORGN
ORGN
Q4 25
$-18.0M
Q3 25
$-1.8M
$-13.5M
Q2 25
$-1.7M
$-16.0M
Q1 25
$-3.6M
$-15.4M
Q4 24
$-696.3K
$-9.5M
Q3 24
$-16.0M
Q2 24
$-1.5M
$-15.6M
Q1 24
$-310.3K
$-18.7M
FCF Margin
IVF
IVF
ORGN
ORGN
Q4 25
-596.6%
Q3 25
-101.6%
-290.5%
Q2 25
-92.6%
-275.4%
Q1 25
-216.9%
-284.2%
Q4 24
-40.6%
-103.5%
Q3 24
-194.7%
Q2 24
-82.3%
-221.8%
Q1 24
-19.7%
-273.6%
Capex Intensity
IVF
IVF
ORGN
ORGN
Q4 25
301.4%
Q3 25
0.5%
115.7%
Q2 25
0.5%
149.9%
Q1 25
0.9%
128.8%
Q4 24
4.6%
41.6%
Q3 24
0.0%
31.0%
Q2 24
3.0%
9.0%
Q1 24
3.2%
28.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons